Cellular and molecular biomarkers of long COVID: a sco** review
Summary Background Long-COVID (LC) encompasses diverse symptoms lasting months
after the initial SARS-CoV-2 infection. Symptoms can be debilitating and affect the quality of …
after the initial SARS-CoV-2 infection. Symptoms can be debilitating and affect the quality of …
Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients
Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary
aspergillosis (CAPA) are increasingly recognised as important complications in patients …
aspergillosis (CAPA) are increasingly recognised as important complications in patients …
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
R Arbel, A Peretz, R Sergienko, M Friger… - The Lancet Infectious …, 2023 - thelancet.com
Background In late 2022, the SARS-CoV-2 omicron (B. 1.1. 529) BA. 5 sublineage
accounted for most of the sequenced viral genomes worldwide. Bivalent mRNA vaccines …
accounted for most of the sequenced viral genomes worldwide. Bivalent mRNA vaccines …
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Y Li, MC Choudhary, J Regan, J Boucau… - Science translational …, 2024 - science.org
Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for
prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the …
prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the …
Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
Background Immunocompromised individuals are not optimally protected by COVID-19
vaccines and potentially require additional preventive interventions to mitigate the risk of …
vaccines and potentially require additional preventive interventions to mitigate the risk of …
High burden of COVID-19-associated pulmonary aspergillosis in severely immunocompromised patients requiring mechanical ventilation
Abstract Background Coronavirus disease 2019 (COVID-19)–associated pulmonary
aspergillosis (CAPA) is a frequent superinfection in critically ill patients with COVID-19 and …
aspergillosis (CAPA) is a frequent superinfection in critically ill patients with COVID-19 and …
COVID-19: Clinical features
K McIntosh, MS Hirsch, A Bloom - Uptodate Version, 2021 - uptodate.com
Coronaviruses are important human and animal pathogens. At the end of 2019, a novel
coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in …
coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in …
[HTML][HTML] Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA …
Background Data on the protection conferred by COVID-19 vaccination and previous SARS-
CoV-2 infection against omicron (B. 1.1. 529) infection in young children are scarce. We …
CoV-2 infection against omicron (B. 1.1. 529) infection in young children are scarce. We …
[HTML][HTML] Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled …
Background COVID-19 continues to be a major health threat, particularly among at-risk
groups, including individuals aged 60 years or older and people with particular medical …
groups, including individuals aged 60 years or older and people with particular medical …
[HTML][HTML] Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …